Oldest pages

Jump to navigation Jump to search

Showing below up to 100 results in range #201 to #300.

View (previous 100 | next 100) (20 | 50 | 100 | 250 | 500)

  1. Air-kerma, incident‏‎ (17:32, 12 September 2019)
  2. Air-kerma, product‏‎ (17:33, 12 September 2019)
  3. Alimentary tract transfer factor‏‎ (17:34, 12 September 2019)
  4. Alpha decay‏‎ (17:35, 12 September 2019)
  5. Alveolar-interstitial region‏‎ (17:35, 12 September 2019)
  6. Angiogenesis‏‎ (17:35, 12 September 2019)
  7. Annihilation photons‏‎ (17:36, 12 September 2019)
  8. Annual dose‏‎ (17:36, 12 September 2019)
  9. Area monitoring‏‎ (17:37, 12 September 2019)
  10. Auger transition‏‎ (17:37, 12 September 2019)
  11. Authorization‏‎ (17:38, 12 September 2019)
  12. Authorized limit‏‎ (17:38, 12 September 2019)
  13. Autoimmune disease‏‎ (17:39, 12 September 2019)
  14. Autonomy‏‎ (17:39, 12 September 2019)
  15. Averted dose‏‎ (17:40, 12 September 2019)
  16. Wisdom‏‎ (17:43, 12 September 2019)
  17. Waste disposal‏‎ (17:43, 12 September 2019)
  18. Background dose (rate)‏‎ (18:55, 12 September 2019)
  19. Basal cell‏‎ (18:56, 12 September 2019)
  20. Benthic‏‎ (18:57, 12 September 2019)
  21. Beta-minus decay‏‎ (18:57, 12 September 2019)
  22. Beta-plus decay‏‎ (18:58, 12 September 2019)
  23. Biomedical research volunteer‏‎ (18:58, 12 September 2019)
  24. Bioturbation‏‎ (18:59, 12 September 2019)
  25. Bone marrow‏‎ (18:59, 12 September 2019)
  26. Bradycardia‏‎ (18:59, 12 September 2019)
  27. Branching fraction‏‎ (18:59, 12 September 2019)
  28. Bronchial region‏‎ (19:00, 12 September 2019)
  29. Bystander effect‏‎ (19:00, 12 September 2019)
  30. Qualified expert‏‎ (19:03, 12 September 2019)
  31. Occupational exposure‏‎ (19:07, 12 September 2019)
  32. Orphan source‏‎ (19:07, 12 September 2019)
  33. Oversight‏‎ (19:07, 12 September 2019)
  34. Cardiac arrhythmias‏‎ (19:15, 12 September 2019)
  35. Cardiac valve diseases‏‎ (19:16, 12 September 2019)
  36. Cardiomyopathy‏‎ (19:16, 12 September 2019)
  37. Cardioverter-defibrillator‏‎ (19:16, 12 September 2019)
  38. Chronic exposure‏‎ (19:17, 12 September 2019)
  39. Class SR-0 gases‏‎ (19:17, 12 September 2019)
  40. Class SR-1 gases‏‎ (19:17, 12 September 2019)
  41. Class SR-2 gases‏‎ (19:18, 12 September 2019)
  42. Clearance level‏‎ (19:19, 12 September 2019)
  43. Clonogenic cells‏‎ (19:19, 12 September 2019)
  44. Clonogenic survival‏‎ (19:19, 12 September 2019)
  45. Co-expertise‏‎ (19:19, 12 September 2019)
  46. Colony‏‎ (19:20, 12 September 2019)
  47. Committed effective dose‏‎ (19:20, 12 September 2019)
  48. Committed equivalent dose‏‎ (19:20, 12 September 2019)
  49. Complex tissues‏‎ (19:21, 12 September 2019)
  50. Computed tomography dose index‏‎ (19:21, 12 September 2019)
  51. Connective tissue‏‎ (19:21, 12 September 2019)
  52. Consequential late effects‏‎ (19:21, 12 September 2019)
  53. Constancy test‏‎ (19:21, 12 September 2019)
  54. Contamination‏‎ (19:22, 12 September 2019)
  55. Coronary heart disease‏‎ (19:23, 12 September 2019)
  56. Cost-benefit analysis‏‎ (19:24, 12 September 2019)
  57. Coster-Kronig transition‏‎ (19:25, 12 September 2019)
  58. Curie‏‎ (19:25, 12 September 2019)
  59. Cytokines‏‎ (19:26, 12 September 2019)
  60. Decay constant‏‎ (19:28, 12 September 2019)
  61. Decommissioning‏‎ (19:28, 12 September 2019)
  62. Decontamination‏‎ (19:29, 12 September 2019)
  63. Decontamination factor‏‎ (19:29, 12 September 2019)
  64. Deontological Ethics‏‎ (19:30, 12 September 2019)
  65. Diastasis‏‎ (19:30, 12 September 2019)
  66. Dichotomous‏‎ (19:31, 12 September 2019)
  67. Differentiation‏‎ (19:31, 12 September 2019)
  68. In vivo radiobioassay‏‎ (19:32, 12 September 2019)
  69. Disposal‏‎ (19:33, 12 September 2019)
  70. DNA damage signalling‏‎ (19:33, 12 September 2019)
  71. Dose constraint‏‎ (19:35, 12 September 2019)
  72. Dose criteria‏‎ (19:35, 12 September 2019)
  73. Dose limit‏‎ (19:36, 12 September 2019)
  74. Dose per unit intake coefficient‏‎ (19:37, 12 September 2019)
  75. Dose rate‏‎ (19:38, 12 September 2019)
  76. Dose rate effectiveness factor‏‎ (19:38, 12 September 2019)
  77. Dose-rate effect‏‎ (19:39, 12 September 2019)
  78. Dose-threshold‏‎ (19:40, 12 September 2019)
  79. Early normal tissue responses‏‎ (19:43, 12 September 2019)
  80. Edema‏‎ (19:44, 12 September 2019)
  81. Effect Dose 50‏‎ (19:45, 12 September 2019)
  82. Effective charge number‏‎ (19:46, 12 September 2019)
  83. Effective dose equivalent‏‎ (19:47, 12 September 2019)
  84. Effective half-life‏‎ (19:49, 12 September 2019)
  85. Electron-capture decay‏‎ (19:49, 12 September 2019)
  86. Electrophysiology‏‎ (19:51, 12 September 2019)
  87. Emergency‏‎ (19:52, 12 September 2019)
  88. Emergency exposure situation‏‎ (19:52, 12 September 2019)
  89. Emergency plan‏‎ (19:53, 12 September 2019)
  90. Emergency preparedness‏‎ (19:53, 12 September 2019)
  91. Emergency procedures‏‎ (19:53, 12 September 2019)
  92. Endogeneous excretion‏‎ (19:54, 12 September 2019)
  93. Environmental exposure‏‎ (19:55, 12 September 2019)
  94. Environmental radiation protection‏‎ (19:55, 12 September 2019)
  95. Epithelium‏‎ (19:56, 12 September 2019)
  96. Erythropoietin‏‎ (19:57, 12 September 2019)
  97. Ethics‏‎ (19:58, 12 September 2019)
  98. Exempt waste‏‎ (19:59, 12 September 2019)
  99. Exemption level‏‎ (19:59, 12 September 2019)
  100. Existing exposure situation‏‎ (20:00, 12 September 2019)

View (previous 100 | next 100) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:AncientPages"